Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Study of MD-7246 Administered Orally for 12 Weeks to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

Next Previous
Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Study of MD-7246 Administered Orally for 12 Weeks to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linaclotide (Primary)
  • Indications Abdominal pain; Irritable bowel syndrome
  • Focus Therapeutic Use
  • Sponsors Ironwood Pharmaceuticals

Most Recent Events

  • 02 Nov 2022 Results assessing efficacy, safety and dose-response of MD-7246 in patients with irritable bowel syndrome with diarrhoea, published in the Alimentary Pharmacology and Therapeutics.
  • 23 May 2021 Results of post-hoc analysis assessing abdominal pain effects based on time since diagnosis, presented at the Digestive Disease Week 2021.
  • 17 May 2021 According to an Ironwood Pharmaceuticals media release, data from this study will be presented at the Digestive Disease Week (DDW) 2021 virtual meeting, May 21 - May 23, 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top